Tal Zaks, MD, PhD, explains the mechanism of action of SAR302503, a TKI being investigated in a phase III trial in patients with intermediate-2 or high-risk myelofibrosis.
Tal Zaks, MD, PhD
Articles by Tal Zaks, MD, PhD
Latest Updated Articles
The Mechanism of Action of SAR302503Published: May 9th 2013 | Updated: